Molecular Characterization of Human Prostate Carcinoma Cell Lines

Prostate

Volumn 57, Issue 3, 2003, Pages 205-225

  Van Bokhoven, Adrie ^a   Varella Garcia, Marileila ^a   Korch, Christopher ^b   Johannes, Widya U ^a   Smith, E Erin ^a   Miller, Heidi L ^a   Nordeen, Steven K ^a   Miller, Gary J ^a   Lucia, M Scott ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Androgen receptor; Cross contamination; DNA profiling; Karyotype; Keratin; p53

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN; CYTOKERATIN 18; CYTOKERATIN 8; KERATIN 5; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BASAL CELL; CANCER CELL; CANCER CELL CULTURE; CANCER STAGING; CELL TYPE; CHROMOSOME G BAND; CONTROLLED STUDY; CROSS CONTAMINATION; CYTOGENETICS; DNA FINGERPRINTING; GENE; GENE MUTATION; GENETIC CORRELATION; GENETIC CROSS; HELA CELL; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPING; MOLECULAR DYNAMICS; NEUROSECRETORY CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

BLOTTING, WESTERN; CARCINOMA; CELL LINE, TUMOR; DNA FINGERPRINTING; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; KERATINS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0142075168     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10290     Document Type: Article

References (105)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer Statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Burrows MT, Burns JE, Suzuki Y. Studies on the growth of cells. The cultivation of bladder and prostatic tumors outside the body. J Urol 1917;1:3-15.
3. Fraley EE, Ecker S, Vincent MM. Spontaneous in vitro neoplastic transformation of adult human prostatic epithelium. Science 1970;170:540-542.
4. Williams RD. Human urologic cancer cell lines. Invest Urol 1980;17:359-363.
5. Nelson-Rees WA, Flandermeyer RR. HeLa cultures defined. Science 1976;191:96-98.
6. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF, Kelland LR, Harrison M, Virmani A, Ward TH, Ayres KL, Debenham PG. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 2001;98:8012-8017.
7. van Bokhoven A, Varella-Garcia M, Korch C, Hessels D, Miller GJ. Widely used prostate carcinoma cell lines share common origins. Prostate 2001;47:36-51.
8. Pan Y, Lui WO, Nupponen N, Larsson C, Isola J, Visakorpi T, Bergerheim US, Kytola S. 5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines. Genes Chromosomes Cancer 2001;30:187-195.
9. Varella-Garcia M, Boomer T, Miiler GJ. Karyotypic similarity identified by multiplex-FISH relates four prostate adenocarcinoma cell lines: PC-3, PPC-1, ALVA-31, and ALVA-41. Genes Chromosomes Cancer 2001;31:303-315.
10. Chen TR. Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. Cytogenet Cell Genet 1993;62:183-184.
11. MacLeod RA, Dirks WG, Matsuo Y, Kaufmann M, Milch H, Drexler HG. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999;83:555-563.
12. van Bokhoven A, Varella-Garcia M, Korch C, Miller GJ. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 2001;61:6340-6344.
13. van Leenders GJ, Dijkman H, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80:1251-1258.
14. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-1775.
15. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996;28:98-106.
16. Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, Masters JR. Epithelial cell differentiation pathways in the human prostate: Identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 2001;49:271-278.
17. Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 1992;52:6182-6187.
18. Hudson DL, O'Hare M, Watt FM, Masters JR. Proliferative heterogeneity in the human prostate: Evidence for epithelial stem cells. Lab Invest 2000;80:1243-1250.
19. Aygun C. Small cell carcinoma of the prostate: A case report and review of the literature. Md Med J 1997;46:353-356.
20. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985;45:3663-3667.
21. Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: A study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 1999;23:147-152.
22. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001;195:563-570.
23. Googe PB, McGinley KM, Fitzgibbon JF. Anticytokeratin antibody 34 beta E12 staining in prostate carcinoma. Am J Clin Pathol 1997;107:219-223.
24. Gil-Diez de Medina S, Salomon L, Colombel M, Abbou CC, Bellot J, Thiery JP, Radvanyi F, van der Kwast TH, Chopin DK. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998;29:1005-1012.
25. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation, and androgen receptor status. Ann Oncol 2001;12(Suppl 2):S141-S144.
26. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
27. Mickey DD, Stone KR, Wunderli H, Mickey GH, Vollmer RT, Paulson DF. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res 1977;37:4049-4058.
28. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-281.
29. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW, Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
30. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. The LNCaP cell line - A new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
31. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
32. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-5979.
33. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, Resnick MI, Seftel A, Pretlow TG. CWR22 - Androgen-dependent xenograft model derived from a primary human prostatic-carcinoma. Cancer Res 1994;54:6049-6052.
34. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-3046.
35. Kruse CA, Varella-Garcia M, Kleinschmidt-DeMasters BK, Owens GC, Spector EB, Fakhrai H, Savelieva E, Liang BC. Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines. In Vitro Cell Dev Biol Anim 1998;34:455-462.
36. ISCN. Guidelines for cancer cytogenetics: An international system for human cytogenetics nomenclature (1995). Basel: S. Karger AG; 1995. 114 p.
37. Mehta PP, Lokeshwar BL, Schiller PC, Bendix MV, Ostenson RC, Howard GA, Roos BA. Gap-junctional communication in normal and neoplastic prostate epithelial cells and its regulation by cAMP. Mol Carcinog 1996;15:18-32.
38. Plymate SR, Loop SM, Hoop RC, Wiren KM, Ostenson R, Hryb DJ, Rosner W. Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma. J Steroid Biochem Mol Biol 1991;40:833-839.
39. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996;93:15152-15157.
40. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-409.
41. Lee YG, Korenchuk S, Lehr J, Whitney S, Vessela RA, Pienta KJ. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 2001;15:157-162.
42. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997;3:2493-2500.
43. Kim CJ, Kushima R, Okada Y, Seto A. Establishment and characterization of a prostatic small-cell carcinoma cell line (PSK-1) derived from a patient with Klinefelter syndrome. Prostate 2000;42:287-294.
44. Grossman HB, Wedemeyer G, Ren L, Carey TE. UM-SCP-1, a new human cell line derived from a prostatic squamous cell carcinoma. Cancer Res 1984;44:4111-4117.
45. Korenchuk S, Lehr JE, McLean L, Lee YG, Whitney S, Vessela RA, Lin DL, Pienta KJ. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001;15:163-168.
46. Williams RD, Bronson DL, Elliott AY, Gehrke CW, Kuo K, Fraley EE. Biochemical markers of cultured human prostatic epithelium. J Urol 1978;119:768-771.
47. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH, Minna JD. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913-2923.
48. Johnson BE, Whang-Peng J, Naylor SL, Zbar B, Brauch H, Lee E, Simmons A, Russell E, Nam MH, Gazdar AF. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J Natl Cancer Inst 1989;81:1223-1228.
49. Hartley-Asp B, Billström A, Kruse E. Identification by C-banding of two human prostate tumour cell lines, 1013L and DU 145. Int J Cancer 1989;44:161-164.
50. Gregory CW, Johnson RT Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-2898.
51. Gingrich JR, Tucker JA, Walther PJ, Day JW, Poulton SH, Webb KS. Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). J Urol 1991;146:915-919.
52. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun AS, Witte ON, Sawyers CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-408.
53. Claas FH, van Steenbrugge GJ. Expression of HLA-like structures on a permanent human tumor line PC-93. Tissue Antigens 1983;21:227-232.
54. Romijn JC, Erkens-Schulze S, Van Weerden WM, Teubel W, Trapman J, Schroder FH. Development and characterization of a new in vitro model to study the mechanisms of prostate cancer progression. Urol Res 1995;23:265.
55. Romijn JC, Erkens-Schulze S, Schroder FH. Perspectives of the use of tissue culture methods as an alternative to human prostate cancer xenografts in nude mice. In: Arnold W, Köpf-Maier P, Michael B, editors. Contributions to Oncology: Immunodeficient animals: Models for cancer research, Vol. 51. Basel: S. Karger AG; 1996. pp 209-213.
56. Nelson-Rees WA, Flandermeyer RR. Karyotyping of prostatic carcinoma cell line. Int J Cancer 1978;21:796-797.
57. Pan Y, Kytola S, Farnebo F, Wang N, Lui WO, Nupponen N, Isola J, Visakorpi T, Bergerheim US, Larsson C. Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet 1999;87:225-232.
58. Macville M, Schrock E, Padilla N, Keck C, Ghadimi BM, Zimonjic D, Popescu N, Ried T. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res 1999;59:141-150.
59. Kochera M, Depinet TW, Pretlow TP, Giaconia JM, Edgehouse NL, Pretlow TG, Schwartz S. Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors. Prostate 1999;41:7-11.
60. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000;6:1038-1045.
61. van Bokhoven A, Caires A, Di Maria A, Passarini Schulte A, Lucia MS, Nordeen SK, Miller GJ, Varella-Garcia M. Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate 2003;57:226-244.
62. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: A model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 2000;6:1190-1197.
63. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001;47:66-75.
64. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002;62:6606-6614.
65. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, de Vere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-459.
66. Fan K. Heterogeneous subpopulations of human prostatic adenocarcinoma cells: Potential usefulness of P21 protein as a predictor for bone metastasis. J Urol 1988;139:318-322.
67. Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, Rhim JS, Nanus DM, Gudas LJ. Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res 2002;62:1654-1661.
68. Okada H, Shirakawa T, Miyake H, Gotoh A, Fujisawa M, Arakawa S, Kamidono S. Establishment of a prostatic small-cell carcinoma cell line (SO-MI). Prostate 2003;56:231-238.
69. Webber MM, Horan PK, Bouldin TR. Present status of MA-160 cell line. Prostatic epithelium or HeLa cells? Invest Urol 1977;14:335-343.
70. Nelson-Rees WA, Flandermeyer RR, Hawthorne PK. Banded marker chromosomes as indicators of intraspecies cellular contamination. Science 1974;184:1093-1096.
71. Metcalfe SA, Whelan RD, Masters JR, Hill BT. In vitro responses of human prostate tumour cell lines to a range of antitumour agents. Int J Cancer 1983;32:351-358.
72. Lubaroff DM. Development of an epithelial tissue culture line from human prostatic adenocarcinoma. J Urol 1977;118:612-615.
73. Lubaroff DM. HPC-36: An epithelial tissue culture line derived from human prostate adenocarcinoma. Natl Cancer Inst Monogr 1978;49:35-39.
74. Tanabe H, Takada Y, Minegishi D, Korematsu M, Masui T, Mizusawa H. Cell line individualization by STR multiplex system in the cell bank found cross contamination between ECV304 and EJ-1/T24. Tissue Cult Res Commun 1999;18:329-338.
75. Chu PG, Lyda MH, Weiss LM. Cytokeratin 14 expression in epithelial neoplasms: A survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours. Histopathology 2001;39:9-16.
76. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/ 6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-830.
77. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135-148.
78. Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, Burstein DE. p63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 2002;33:921-926.
79. Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 1984;54:3078-3084.
80. Downing SR, Jackson P, Russell PJ. Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression: A review of the evidence. Urol Oncol 2001;6:103-110.
81. Stapleton AM, Timme TL, Gousse AE, Li QF, Tobon AA, Kattan MW, Slawin KM, Wheeler TM, Scardino PT, Thompson TC. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997;3:1389-1397.
82. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999;161:304-308.
83. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995;147:92-101.
84. Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun AS, Ramon J, Eshhar Z. WISH-PC2: A unique xenograft model of human prostatic small cell carcinoma. Cancer Res 2000;60:6563-6567.
85. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 1999;14:1-8.
86. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-540.
87. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-2581.
88. Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 1998;12:941-953.
89. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997;11:148-161.
90. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette JM, Stower MJ, Maitland NJ. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002;52:253-263.
91. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993;23:123-134.
92. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;51:4716-4720.
93. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 1999;162:2192-2199.
94. Zhao XY, Peehl DM, Navone NM, Feldman D. 1α,25-Dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000;141:2548-2556.
95. Okada K, Schroder FH. Human prostatic carcinoma in cell culture: Preliminary report on the development and characterization of an epithelial cell line (EB 33). Urol Res 1974;2:111-121.
96. Pontes JE, Choe B, Rose N, Pierce JM. Immunochemical identification of prostatic epithelial cells in culture. Invest Urol 1979;16:483-485.
97. Iizumi T, Yazaki T, Kanoh S, Kondo I, Koiso K. Establishment of a new prostatic carcinoma cell line (TSU-Pr1). J Urol 1987;137:1304-1306.
98. Muraki J, Addonizio JC, Choudhury MS, Fischer J, Eshghi M, Davidian MM, Shapiro LR, Wilmot PL, Nagamatsu GR, Chiao JW. Establishment of new human prostatic cancer cell line (JCA-1). Urology 1990;36:79-84.
99. Schmelz M, Cress AE, Barrera J, McDaniel KM, Davis TL, Fuchs L, Dalkin BL, Nagle RB. PEAZ-1: A new human prostate neoplastic epithelial cell line. Prostate 2001;48:79-92.
100. Nagle RB. Letter: PEAZ-1: A new human prostate neoplastic epithelial cell line. 2003. In press: The Prostate.
101. Brothman AR, Lesho LJ, Somers KD, Wright GL Jr., Merchant DJ. Phenotypic and cytogenetic characterization of a cell line derived from primary prostatic carcinoma. Int J Cancer 1989;44:898-903.
102. Narayan P, Dahiya R. Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1). J Urol 1992;148:1600-1604.
103. Loop SM, Rozanski TA, Ostenson RC. Human primary prostate tumor cell line, ALVA-31: A new model for studying the hormonal regulation of prostate tumor cell growth. Prostate 1993;22:93-108.
104. van Helden PD, Wiid IJ, Hoal-van Helden EG, Bey E, Cohen R. Detection by DNA fingerprinting of somatic changes during the establishment of a new prostate cell line. Br J Cancer 1994;70:195-198.
105. Nakhla AM, Rosner W. Characterization of ALVA-41 cells, a new human prostatic cancer cell line. Steroids 1994;59:586-589.